Trial Profile
An Open-Label Study of Aripiprazole (Abilify) as an Augmentation Agent in Patients With Treatment-Resistant Depression.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2009
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 11 Oct 2008 New trial record.